SAB Biotherapeutics
SABS
SABS
22 hedge funds and large institutions have $9.69M invested in SAB Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Holders
22
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$310K | |
| 2 | +$60K | |
| 3 | +$23K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.97K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$511 |
Top Sellers
| 1 | -$832K | |
| 2 | -$468K | |
| 3 | -$12.6K | |
| 4 |
Millennium Management
New York
|
-$3.92K |
| 5 |
SWC
Spectrum Wealth Counsel
Indianapolis,
Indiana
|
-$2.28K |